恒瑞医药HRS9531注射液Ⅲ期临床试验数据亮相美国肥胖周大会

Core Viewpoint - HengRui Medicine and Kailera Therapeutics have announced significant results from the Phase III clinical trial of the GLP-1/GIP dual receptor agonist HRS9531, demonstrating substantial weight loss compared to the placebo group [1] Group 1: Clinical Trial Results - After 48 weeks of treatment, the average weight loss percentage in the HRS9531 groups was significantly better than that of the placebo group, with the 6 mg group achieving an average weight loss of 19.2% [1] - Previous Phase II clinical trial results indicated that the 8 mg group had an average weight loss of 23.6% [1] Group 2: Future Plans - HengRui Medicine has submitted a new drug application, while Kailera plans to initiate global Phase III clinical trials by the end of the year [1]